CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Empagliflozin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01451775
NCT01451775Phase 1Completed

Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects

Boehringer Ingelheim·interventional·Posted Oct 14, 2011·Updated Jun 27, 2014

In Brief

A Phase 1 clinical trial evaluating Empagliflozin for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 14, 2011
Enrollment StartOct 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.7 years ago

Interventions

Empagliflozindrug

high dose of empagliflozin after overnight fasting for at least 10 h

Empagliflozindrug

low dose empagliflozin after overnight fasting for at least 10 h

Empagliflozindrug

high dose of empagliflozin after a standardised high fat breakfast